5-chloropyridine-2-carbothioamide | 499796-72-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 5-chloropyridine-2-carbothioamide
• CAS: 499796-72-4
• 化学式: C₆H₅ClN₂S
• 分子量: 172.638
• InChiKey: FCXQEGCLAGPNPO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  71
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 储存条件：
  室温

反应信息

• 作为反应物：
  描述：

  5-chloropyridine-2-carbothioamide 在 碳酸氢钠 作用下， 以 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 生成 2-amino-6-{[2-(4-chloropyridine)thiazol-4-yl]methylthio}-4-(4-methoxyphenyl)pyridine-3,5-dicarbonitrile
  参考文献：
  名称：

  Structure-kinetics relationships of Capadenoson derivatives as adenosine A 1 receptor agonists

  摘要：

  We report the synthesis and biological evaluation of new derivatives of Capadenoson, a former drug candidate that was previously advanced to phase Ha clinical trials. 19 of the 20 ligands show an affinity below 100 nM at the human adenosine A(1) receptor (hA(1)AR) and display a wide range of residence times at this target (from approx. 5 min (compound 10) up to 132 min (compound 5)). Structure-affinity and structure-kinetics relationships were established, and computational studies of a homology model of the hA(1)AR revealed crucial interactions for both the affinity and dissociation kinetics of this family of ligands. These results were also combined with global metrics (Ligand Efficiency, cLogP), showing the importance of binding kinetics as an additional way to better select a drug candidate amongst seemingly similar leads. (C) 2015 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2015.07.023
• 作为产物：
  描述：

  2-氰基-5-氯吡啶 在 ammonium sulfide 、 三乙胺 作用下， 以 吡啶 为溶剂， 以57%的产率得到5-chloropyridine-2-carbothioamide
  参考文献：
  名称：

  Structure-kinetics relationships of Capadenoson derivatives as adenosine A 1 receptor agonists

  摘要：

  We report the synthesis and biological evaluation of new derivatives of Capadenoson, a former drug candidate that was previously advanced to phase Ha clinical trials. 19 of the 20 ligands show an affinity below 100 nM at the human adenosine A(1) receptor (hA(1)AR) and display a wide range of residence times at this target (from approx. 5 min (compound 10) up to 132 min (compound 5)). Structure-affinity and structure-kinetics relationships were established, and computational studies of a homology model of the hA(1)AR revealed crucial interactions for both the affinity and dissociation kinetics of this family of ligands. These results were also combined with global metrics (Ligand Efficiency, cLogP), showing the importance of binding kinetics as an additional way to better select a drug candidate amongst seemingly similar leads. (C) 2015 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2015.07.023

文献信息

• CYANOTRIAZOLE COMPOUNDS
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：US20160229816A1

  公开（公告）日：2016-08-11

  This invention relates to a cyanotriazole compound represented by the formula (1): wherein each symbols are defined in the specification, or a salt thereof. The compound or a salt thereof stimulates the citric acid cycle activity and/or improves hyperglycemia with less side effects, and excellent safety, and therefore, it is useful for treating and/or preventing diseases or disorders on which citric acid cycle activation and/or improvement of hyperglycemia has a prophylactic and/or therapeutic effect, for example, diabetes, impaired glucose tolerance, insulin resistance, diabetic complications, obesity, dyslipidemia, hepatic steatosis, atherosclerosis and/or cardiovascular disease, as well as diseases or disorders that would benefit from stimulating energy expenditure.

  本发明涉及一种由式（1）表示的氰基三唑化合物，其中每个符号在规范中有定义，或其盐。该化合物或其盐刺激柠檬酸循环活性和/或改善高血糖症的副作用较小，安全性优异，因此，它对于治疗和/或预防柠檬酸循环激活和/或改善高血糖症具有预防和/或治疗作用的疾病或疾病具有用处，例如糖尿病、糖耐量受损、胰岛素抵抗、糖尿病并发症、肥胖症、血脂异常、脂肪肝、动脉粥样硬化和/或心血管疾病，以及那些从刺激能量消耗中受益的疾病或疾病。
• Cyanotriazole compounds
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：US10626095B2

  公开（公告）日：2020-04-21

  This invention relates to a cyanotriazole compound represented by the formula (1): wherein each symbols are defined in the specification, or a salt thereof. The compound or a salt thereof stimulates the citric acid cycle activity and/or improves hyperglycemia with less side effects, and excellent safety, and therefore, it is useful for treating and/or preventing diseases or disorders on which citric acid cycle activation and/or improvement of hyperglycemia has a prophylactic and/or therapeutic effect, for example, diabetes, impaired glucose tolerance, insulin resistance, diabetic complications, obesity, dyslipidemia, hepatic steatosis, atherosclerosis and/or cardiovascular disease, as well as diseases or disorders that would benefit from stimulating energy expenditure.

  本发明涉及一种由式（1）表示的氰三唑化合物： 其中各符号在说明书中定义，或其盐。该化合物或其盐可刺激柠檬酸循环活性和/或改善高血糖，且副作用小、安全性高，因此可用于治疗和/或预防柠檬酸循环激活和/或改善高血糖具有预防和/或治疗作用的疾病或紊乱、例如，糖尿病、糖耐量受损、胰岛素抵抗、糖尿病并发症、肥胖症、血脂异常、肝脂肪变性、动脉粥样硬化和/或心血管疾病，以及可从刺激能量消耗中获益的疾病或紊乱。
• Structure-kinetics relationships of Capadenoson derivatives as adenosine A 1 receptor agonists
  作者：Julien Louvel、Dong Guo、Marjolein Soethoudt、Tamara A.M. Mocking、Eelke B. Lenselink、Thea Mulder-Krieger、Laura H. Heitman、Adriaan P. IJzerman

  DOI：10.1016/j.ejmech.2015.07.023

  日期：2015.8

  We report the synthesis and biological evaluation of new derivatives of Capadenoson, a former drug candidate that was previously advanced to phase Ha clinical trials. 19 of the 20 ligands show an affinity below 100 nM at the human adenosine A(1) receptor (hA(1)AR) and display a wide range of residence times at this target (from approx. 5 min (compound 10) up to 132 min (compound 5)). Structure-affinity and structure-kinetics relationships were established, and computational studies of a homology model of the hA(1)AR revealed crucial interactions for both the affinity and dissociation kinetics of this family of ligands. These results were also combined with global metrics (Ligand Efficiency, cLogP), showing the importance of binding kinetics as an additional way to better select a drug candidate amongst seemingly similar leads. (C) 2015 Elsevier Masson SAS. All rights reserved.